11 Ways to Start a GLP-1 Program That Actually Justifies the Cost

Starting a GLP-1 program is not complicated. But paying too much, choosing the wrong pharmacy model, or skipping labs because a platform skipped them for you can make the whole thing a mess. Here is what to look for across the providers actually worth considering in 2026.

1. HealthRX: Best Starting Point for Cash-Pay Buyers

Compounded semaglutide from $99 a month and compounded tirzepatide from $149 a month puts HealthRX at the low end of what any credible telehealth provider is charging right now. What makes that price less suspicious than it sounds: the medication comes from Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot-tracked batches and LegitScript certification (cert 50087439). That is a named, traceable source, not an anonymous lab. The physician review takes roughly 24 hours after you complete the health assessment online, and overnight shipping to all 50 states is free. The clinical trial data the platform references, roughly 21% body weight reduction at 72 weeks for tirzepatide in SURMOUNT-1 and roughly 15% for semaglutide at 68 weeks in STEP 1, comes from real published studies, not brand copy. Compounded medications are not FDA-approved, so that caveat stands regardless of the pharmacy’s quality controls.

Verdict: The most accessible entry price among credible compounded GLP-1 providers, with a verifiable pharmacy and fast fulfillment.

2. FormBlends: Best for Buyers Who Want Published Lab Results

If you want to see the actual purity numbers before injecting anything, FormBlends publishes per-product test results including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility data. Most GLP-1 telehealth brands do not do this at all. Physician oversight is built into the model, dispensing goes through an FDA-registered 503A compounding pharmacy, and the catalog extends beyond GLP-1s into recovery, longevity, and cognitive peptides. Cash pricing runs higher than HealthRX, around $299 for semaglutide and $349 for tirzepatide per vial. Fulfillment covers 47 states rather than the full continental map. For someone who values documented quality assurance over entry-level pricing, or who wants GLP-1 treatment alongside other peptide protocols from a single provider, FormBlends is a logical choice.

Verdict: Higher price point than HealthRX, but published purity documentation sets it apart from nearly every other option on this list.

3. Mochi Health: Best for Obesity-Medicine Oversight

Mochi puts board-certified obesity-medicine physicians in the loop, not just general practitioners doing a quick sign-off. Monthly cash pricing lands around $99 for compounded semaglutide and $199 for compounded tirzepatide. The monitoring is more hands-on than bare-minimum platforms. Worth knowing: obesity-medicine certification means the clinician’s training is specifically focused on weight, metabolic factors, and medication management together.

Verdict: Solid monitoring and low compounded pricing, though tirzepatide costs more here than at HealthRX.

4. Hims & Hers: Best for Branded Meds with Savings Card Access

After the March 2026 Novo Nordisk settlement, Hims & Hers shifted away from compounded GLP-1s and now sells branded medications. Injectable Wegovy runs around $299 a month, oral semaglutide around $249, and Zepbound around $399. With insurance and manufacturer savings cards, that can drop to $0 to $25 for eligible patients. If you have insurance and want FDA-approved branded options through a slick app, this setup works well.

Verdict: Expensive without insurance, genuinely affordable with it. Not the right path for cash-pay patients.

5. Ro Body: Best for Prior-Authorization Support

Ro charges about $39 for the first month, then $74 to $149 per month, with medications billed separately. The program has a dedicated prior-authorization team, which matters more than most people realize when trying to get branded GLP-1s covered. They accept insurance for branded medications.

Verdict: The prior-auth support is a real, practical advantage. Budget carefully since medication costs stack on top of the membership fee.

6. PlushCare: Best for Same-Day Appointments

PlushCare’s membership is $19.99 a month, among the cheapest platforms on this list, and they offer same-day video visits with clinicians who can prescribe branded GLP-1s. Insurance is accepted. They are not a weight-loss-only telehealth company, which means the GLP-1 experience is part of a broader primary care model rather than a specialized program.

Verdict: Fastest access to a clinician. Better for someone who already knows what medication they want than for someone needing guidance.

7. Henry Meds: Best for Speed Without Heavy Monitoring

Henry Meds ships compounded GLP-1s in 24 to 72 hours, faster than most. Cash pricing starts around $179 to $249 for the first month. The monitoring is lighter than what you get from Mochi or Calibrate, which is either a feature or a drawback depending on how much hand-holding you want.

Verdict: Good for straightforward cases where speed matters. Not ideal for people with complex metabolic histories.

8. Found: Best Low-Cost Platform With Coaching

Found charges around $99 a month for the platform and coaching, with medications priced separately. The coaching component is more integrated than what bare-prescription platforms offer. Results vary widely with coaching-heavy models.

Verdict: Reasonable all-in cost if you value behavioral support alongside medication.

9. Eden: Straightforward Compounded Semaglutide

Eden’s compounded semaglutide runs about $149 a month with no contracts. Simple. Not heavy on features, not heavy on oversight. For someone who just wants the medication and a prescription, Eden is functional.

Verdict: No frills, fair price, limited extras.

10. MEDVi: No-Contract Compounded Option

MEDVi starts around $179 for the first month with compounded GLP-1s and no long-term commitment required. The no-contract structure gives you flexibility to stop or switch without financial penalty, which matters when you are still figuring out whether a medication agrees with you.

Verdict: Flexible entry. Worth comparing pharmacy sourcing details before committing.

11. LillyDirect Oral Orforglipron: Best for Needle-Averse Starters

Lilly launched oral orforglipron through LillyDirect around April 2026 at roughly $149 a month. It is an FDA-approved small-molecule GLP-1 agonist, not a peptide injectable. For people who cannot or will not do weekly injections, this is the first genuinely accessible oral option from a major manufacturer.

Verdict: A real alternative to injectables. Relatively new, so long-term real-world data is still accumulating.

Quick Comparison

Provider	Starting Price	Compounded or Branded	Notable Feature
HealthRX	$99/mo sema, $149/mo tirz	Compounded	Named 503A pharmacy, overnight shipping
FormBlends	~$299 sema, ~$349 tirz	Compounded	Published purity testing, peptide catalog
Mochi Health	$99/mo sema	Compounded	Obesity-medicine MDs
Hims & Hers	$249-$399/mo	Branded	Insurance and savings card eligible
Ro Body	$39 first month + meds	Branded	Prior-auth team
PlushCare	$19.99/mo + meds	Branded	Same-day visits
Henry Meds	$179-$249 first month	Compounded	24-72h shipping
Found	$99/mo + meds	Both	Coaching included
Eden	$149/mo	Compounded	No contracts
MEDVi	$179 first month	Compounded	No contracts
LillyDirect	~$149/mo	Branded	Oral, no injection

The right pick depends on whether you are paying cash or using insurance, whether you want a named pharmacy with documented quality controls, and how much clinical oversight you actually need. Prices and program structures shift, so verify current terms directly with each provider before signing up.

Common Questions

Does it matter which compounding pharmacy a GLP-1 telehealth platform uses?

Yes, it matters significantly. A named, traceable pharmacy operating under USP-797 standards, like Manifest Pharmacy used by HealthRX, gives you lot-tracked batches and third-party certification. Anonymous or unverified sources have no such accountability. Ask any compounded GLP-1 provider directly which pharmacy fulfills their prescriptions before you pay.

Can I switch from a compounded GLP-1 program to a branded one later, or does starting compounded lock me in?

Nothing locks you in permanently. Platforms like Hims & Hers now focus on branded medications after the March 2026 Novo Nordisk settlement, and providers like Ro Body accept insurance for branded options. Starting on compounded semaglutide at $99 a month through HealthRX or Eden does not prevent you from transitioning to Wegovy or Zepbound once insurance coverage becomes available to you.

What does FormBlends publish in its lab results, and why don’t other providers do the same?

FormBlends posts HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility data for individual products. Most telehealth GLP-1 providers do not publish this because there is no regulatory requirement to share it publicly. Providing it is a voluntary quality signal, not a legal obligation, which is why it remains uncommon across this category.

If I want a GLP-1 prescription but have a complicated metabolic history, which platform type is safest to start with?

Mochi Health is the most appropriate starting point in that situation. Board-certified obesity-medicine physicians, not general practitioners, review your case. That specialization matters when thyroid history, insulin resistance, or prior medication interactions are part of your picture. Lighter-touch platforms like Henry Meds or Eden are better suited to straightforward cases.

Is oral orforglipron through LillyDirect actually comparable to injectable semaglutide or tirzepatide in terms of results?

Orforglipron is a small-molecule GLP-1 agonist, FDA-approved and sold at roughly $149 a month through LillyDirect. It is not a peptide injectable. Clinical trial data for orforglipron showed meaningful weight reduction, but direct head-to-head comparisons with the 15% to 21% figures from STEP 1 and SURMOUNT-1 are still limited. Real-world long-term data is still accumulating given its April 2026 launch.

Prices, program structures, and pharmacy sourcing details change frequently. Confirm current terms directly with each provider before enrolling.

Sources

• Jastreboff et al., tirzepatide weight-loss outcomes, NEJM, 2022 (SURMOUNT-1)
• Wilding et al., semaglutide weight-loss outcomes, NEJM, 2021 (STEP 1)
• FDA 2026 warning letters to compounding telehealth firms (FDA.gov enforcement actions)
• Novo Nordisk compounded semaglutide settlement, March 9, 2026 (Novo Nordisk press release)
• LegitScript certification registry (LegitScript.com)
• Lilly orforglipron NDA approval and LillyDirect pricing announcement, 2026 (Eli Lilly newsroom)